Do you want to read an article? Please log in or register.
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Hepatology
Related content
Hepatitis
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Lancet.
Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE
doi: 10.1016/S0140-6736(19)32517-6.
Hepatology
Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
J Hepatol.
Newsome PN, Palmer M, Freilich B, Sheikh MY, Sheikh A, Sarles H, Herring R, Mantry P, Kayali Z, Hassanein T, Lee HM, Aithal GP, Volixibat in Adults study group
doi: 10.1016/j.jhep.2020.03.024.
ColonoscopyGastrointestinal CancerInflammatory Bowel Disease
Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol.
Taha AS, McCloskey C, McSkimming P, McConnachie A
doi: 10.1016/
Hepatology
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol
Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, Xu A, Chen X, Zhou C, Ren Z, Yang L, Xu L, Bai Y, Chen L, Li J, Pan H, Cao B, Fang W, Wu W, Wang G, Cheng Y, Yu Z, Zhu X, Jiang D, Lu Y, Wang H, Xu J, Bai L, Liu Y, Lin H, Wu C, Zhang Y, Yan P, Jin C, Zou J
doi: 10.1016/S2468-1253(21)00109-6
RECOMMENDED
Irritable Bowel Syndrome (IBS) and Chronic Constipation
Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
doi: 10.1016/S2468-1253(20)30056-X.
Hepatology
A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease
BMC Gastroenterol
Chong PL, Laight D, Aspinall RJ, Higginson A, Cummings MH
doi: 10.1186/s12876-021-01660-5
Hepatology
Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension
J Hepatol.
Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, Lawitz E, Satapathy SK, Ghabril M, Shiffman ML, Younes ZH, Thuluvath PJ, Berzigotti A, Albillos A, Robinson JM, Hagerty DT, Chan JL, Sanyal AJ, IDN-6556-14 Investigators.
doi: 10.1016/j.jhep.2019.12.010.
Hepatology
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
J Hepatol.
Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC
doi: 10.1016/j.jhep.2019.10.023.
Gastrointestinal Cancer
Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial
Eur J Cancer
Aramaki O, Takayama T, Moriguchi M, Sakamoto H, Yodono H, Kokudo N, Yamanaka N, Kawasaki S, Sasaki Y, Kubota K, Otsuji E, Tanaka S, Matsuyama Y, Fujii M, ACE 500 study group.
doi: 10.1016/j.ejca.2021.08.027